Earnings call transcript: Orthofix beats Q2 2025 forecasts, stock surges

Orthofix Medical Inc (OFIX) reported its second-quarter 2025 earnings, surpassing expectations with an EPS of -0.36 compared to the forecast of -0.41. Revenue reached $203.12 million, exceeding the anticipated $196.16 million. Following the earnings release, Orthofix’s stock surged 15.21% in pre-market trading, reflecting investor optimism. According to InvestingPro data, two analysts have recently revised their earnings estimates upward for the upcoming period, suggesting growing confidence in the company’s trajectory.

Key Takeaways

• Orthofix reported better-than-expected EPS and revenue for Q2 2025.
• The stock price increased by 15.21% in pre-market trading.
• Significant growth was noted in US Orthopedics and Bone Growth Therapies segments.
• New product launches and FDA clearances highlight innovation.
• Positive free cash flow and improved gross margins were achieved.

Company Performance

Orthofix demonstrated robust performance in Q2 2025, with a 4% year-over-year increase in net sales to $200.7 million. The company continued to strengthen its position in the spine and fracture markets, benefiting from a 7% increase in US Spine Fixation procedure volume. Orthofix’s strategic focus on product innovation and market penetration has positioned it well against competitors.

Financial Highlights

• Revenue: $203.12 million, a 4% increase YoY.
• Earnings per share: -0.36, beating the forecast by 12.2%.
• Gross margin: 72.7%, up by 140 basis points.
• Adjusted EBITDA: $20.6 million, representing 10.3% of net sales.
• Positive free cash flow of $4.5 million.

Earnings vs. Forecast

Orthofix exceeded earnings expectations with an EPS of -0.36 against a forecast of -0.41, a positive surprise of 12.2%. Revenue also surpassed forecasts, reaching $203.12 million compared to the expected $196.16 million, marking a 3.55% surprise.

Market Reaction

Following the earnings announcement, Orthofix’s stock price rose to $12.5 in pre-market trading, a 15.21% increase from the previous close of $10.85. This significant movement indicates strong investor confidence in the company’s performance and future prospects. InvestingPro analysis suggests the stock is currently undervalued, with a beta of 0.82 indicating lower volatility than the broader market. For deeper insights into valuation opportunities, explore the Most Undervalued Stocks list on InvestingPro.

Outlook & Guidance

Orthofix projects full-year 2025 net sales between $800 million and $816 million, with an adjusted EBITDA of $82 million to $86 million. The company anticipates continued growth in its US Orthopedics and Bone Growth Therapies segments, supported by upcoming product launches like Xcelsim 2.0. The company’s strong liquidity position is evidenced by a current ratio of 2.71, while maintaining a revenue growth rate of 5.85% over the last twelve months. Discover more financial metrics and 12+ additional ProTips with an InvestingPro subscription, including exclusive access to comprehensive Pro Research Reports covering 1,400+ top stocks.

Executive Commentary

CEO Massimo Colifiori stated, "We are redefining the category of limb reconstruction," emphasizing the company’s innovative pipeline. CFO Julie Andrews added, "We remain focused on disciplined profitable growth," highlighting Orthofix’s strategic priorities.

Risks and Challenges

• Continued negative EPS could concern investors.
• Distributor transitions may pose operational challenges.
• Economic uncertainties could impact market growth.
• Competition in the orthopedic market remains intense.
• Regulatory hurdles for new product approvals.

Q&A

During the earnings call, analysts inquired about the drivers of US Orthopedics growth, to which executives attributed new product launches and market penetration. Discussions also covered stable pricing and cross-selling opportunities across product lines.

Full transcript - Orthofix Medical Inc (OFIX) Q2 2025:

Kayla, Conference Operator: Thank you for standing by. My name is Kayla, and I will be your conference operator today. At this time, I’d like to welcome everyone to the Orthofix Second Quarter twenty twenty five Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question and answer session.

I would now like to turn the call over to Julie Dewey. You may begin.

Julie Dewey, Chief IR and Communications Officer, Orthofix: Thank you, operator, and good morning, everyone. Welcome to Orthofix’s second quarter twenty twenty five earnings call. We appreciate you joining us. I’m Julie Dewey, Orthofix’s Chief IR and Communications Officer. Joining me on the call today are President and Chief Executive Officer, Massimo Colifiori and Chief Financial Officer, Julie Andrews.

Before we get started, please note that our earnings release and the supplemental presentation accompanying this call are available on the Events and Presentations page of the Investors section of our corporate website at orthofix.com. Also, this call is being broadcast live over the Internet to all interested parties, and an archived copy of this webcast will be available in the Investors section of our corporate website shortly after the conclusion of this call. During this call, we’ll be making forward looking statements that involve risks and uncertainties. All statements other than those of historical facts are forward looking statements. We do not undertake any obligation to revise or update such forward looking statements.

Factors that could cause actual results to differ materially are discussed in our most recent filings with the SEC and may be included in our future filings with the SEC. In addition, on today’s call, we will refer to various non GAAP financial measures. Please refer to today’s news release announcing our second quarter twenty twenty five results for information regarding our non GAAP results, including our reconciliations of these non GAAP financial measures to our U. S. GAAP results.

Additionally, and unless otherwise stated, all net sales percentage changes discussed will be on a pro form a constant currency year over year basis, excluding the impact from the discontinuation of the M6 artificial disc product lines and all results of operations that we will refer to will be on a non GAAP as adjusted basis. As we announced on our Q4 earnings call, we are discontinuing the M6 artificial disc product lines. We have posted a pro form a P and L excluding M6 on our website to assist you with updating your models. We will update it on a quarterly basis for the remainder of 2025. Moving to today’s agenda, Massimo will open with comments on our performance and business updates.

Julie Andrews will then review the specifics of our second quarter results and our 2025 financial guidance. With that, I’ll now turn the call over to Massimo.

Massimo Colifiori, President and Chief Executive Officer, Orthofix: Thank you, Julie. Good morning, and thank you for joining us for our second quarter earnings call. I’ll spend some time providing business updates and information about our key initiatives before I turn it over to Julie Andrews to cover the specific of our Q2 results and 2025 guidance. During the second quarter, we continued to execute the priorities that we outlined in our three year plan to transform our business and deliver on our commitment to drive profitable growth. Our second quarter pro form a net sales of $200,700,000 represents year over year constant currency growth of 4%.

Our disciplined approach led to strong adjusted EBITDA margin growth and positive free cash flow generation, underscoring our ability to grow the business responsibly. Strategic initiatives like accelerating spine distributor transition in certain underpenetrated USA territories are gaining traction and creating a powerful foundation for a stronger, more scalable commercial organization to drive our next phase of growth. We expect to benefit from our recent product launches and deliver meaningful product innovation that improves outcomes and efficiencies for our surgeons and their patients. I’m confident the company is well positioned to deliver sustainable long term shareholder value throughout the 2025 and beyond. Now I would like to provide additional detail for each of our businesses.

Our U. A. Spinal fixation net sales grew 5.4% and procedure volume grew 7%, both of which were consistent with our expectation. Importantly, we are off to a strong start accelerating targeted distributor transition in certain USA territories that we announced last quarter. Collectively, these distributors represent a potentially sizable book of business, which we believe will support the above market CAGR of 6.5% to 7.5% reflected in our three year financial plan.

We expect this distributor transition will result in a more robust and scalable commercial organization paving the way for future growth. In addition to this distributor transition, we continue to gain share in our U. S. Anterior lumbar and cervical fusion portfolios, which both grew in excess of 15% significantly outperforming the market. We launched our RIF L Lateral Lumbar Interbody System in The U.

A, the newest addition to our lateral spine portfolio and the final piece in our comprehensive Reef Interbody system. At the same time, we continue to leverage our differentiated 7D flash navigation system to create long standing relationships with our surgeon partners. Total 7D unit placements in The U. S. Grew by 66% in the 2025 compared to the same prior year period, representing total revenue commitment of about 12,000,000 over the life of the contract, which are typically three to four year commitments.

7D earnouts in the first half of this year were ahead of the first half of last year And our focus on driving 70 placements through our Voyager earn out program is delivering sales results with earn out customer exceeding their contracted spinal hardware and biologic purchase commitment by over 50% on average. We believe this demonstrates our ability to drive incremental product pull through with surgeon and seek relationships with surgeons and hospital accounts. As we look at enabling technology driving procedural adoption, we are very excited to announce that we received FDA clearance and initiated the limited market release of our new Virata spinal fixation system in The U. S. Designed to seamlessly integrate with the 7D flash navigation system, Verata exemplifies our commitment to developing implant solutions with enabling technology as a core principle.

This level of compatibility optimize surgical workflows, boosts surgeon confidence and accelerates procedural adoption, all key differentiators that we fully intend to capitalize on. Every aspect of Verada from our proprietary screw design to intuitive instrumentation is engineered for unrivaled ease of use and performance. Virada is more than just another thoracolumbar fixation option. It’s a fully integrated procedural solution designed to empower surgical teams and elevate outcomes in demanding accounts. The limited launch has already generated impressive early traction with over 80% of surgeons participating in the limited launch representing new or incremental business.

These results validates our strategic focus on surgeon driven innovation powered by cutting edge 7D flash technology and reinforces our ability to drive successful market penetration beyond the current customer base. We expect this positive trajectory to continue throughout the limited launch period and look forward to Verada being a meaningful contributor to our growth next year. With continued investment, we expect that our next generation advancements in enabling technology and our hardware portfolio will build upon this unique foundation and establish us as a partner of choice for surgeons seeking real time data driven intraoperative solution in the OR. USA Orthopaedics grew 28% benefiting from strong execution and the launch of our new TRULOC Elevate transfers bond transport system, which is now in full market release globally. This is the fourth consecutive quarter of double digit U.

S. A. Orthopedics growth, validating our strategy to become the market leader in the category of complex limb reconstruction. Since receiving FDA clearance and CE Mark registration earlier this year, over 200 TRULOC Elevate transfer bond transport procedures have been completed, making this is one of the most exciting product launches in Orthofix history. The success of the TRU LOCK Elevate system advances our strategy to become the leading limb reconstruction company in the market and in particular expands our presence in the growing diabetic wound market with an innovative solution designed to improve blood circulation, support wound healing in diabetic feet and lower amputation risk in a challenging patient population.

Building on the success of TRULOC ELEVATE, orthopedic growth in the 2025 is expected to be fueled by a number of new product introduction that we anticipate will capture additional market share with new and existing customers. These innovations include the exclusive FITBON bond transport and lengthening nail and FitBond trochanteric nail. Our unique position as the only company in The U. S. Offering a complete suite of internal and external limb reconstruction solution is yielding substantial results.

This dedicated focus on limb reconstruction is expected to be a crucial growth engine for Orthofix for many years to come as we aim to become the global leader in this $1,700,000,000 market. The BGT team continues to deliver consistent results growing twice the market, solidifying our leadership position in spine and capitalizing on the promising opportunity in fracture. Julie will provide further insights into the performance of the segment. Building our recent product launch successes across the business, we are ideally positioned to deliver transformative innovation that benefits surgeons and patients by optimizing outcomes and efficiencies. We have a healthy commercial pipeline that we believe will provide a clear path to achieving sustained growth that outperforms the market.

We remain focused on three strategic priorities. First, further sharpening our commercial execution to drive deeper market penetration through our comprehensive portfolio offering including the adoption of our 7D flash navigation system second, implementing projects to improve our gross margin and finally, focusing on disciplined capital allocation, adjusted EBITDA expansion and positive free cash flow generation. I believe we are favorably situated to create long term value for our shareholders and to deliver life changing innovation to our patients and surgeons in 2025 and beyond. As we move forward, I’m confident we are well positioned for profitable growth as our efforts to further optimize our Spine commercial channel begin to bear fruit. And we continue to build on our financial foundation and prudently deploy capital to create long term value for our shareholders.

Our momentum continues to build in our Orthopedic business with the groundbreaking opportunity we have to define the limb reconstruction category as well as prospect we have in our bone growth therapy business to further capitalize on cross selling opportunities and drive penetration in the fracturing market with Axle’s team. With that, I’ll now turn the call over to Julie to review our second quarter financial results and our 2025 guidance.

Julie Andrews, Chief Financial Officer, Orthofix: Thank you, Massimo, and good morning, everyone. As we get started, all net sales growth rates that I referred to in my prepared comments will be on a pro form a constant currency basis over the prior year quarter and exclude the impact of net sales related to the discontinuation of the M6 artificial cervical and lumbar disc that we previously announced. These pro form a comparisons are non GAAP financial measures as described by Julie during the introduction of our call. Please refer to the non GAAP reconciliations in our press release and I strongly encourage you to review the information posted on our website. This information includes pro form a results through the 2025 to assist you with your modeling efforts.

During the second quarter, we prioritized investment in Spine and Biologics distribution expansion and investment in surgeon driven innovation. Through rigorous resource allocation efforts, we are focusing on higher return opportunities to further sustain our share capture in U. S. Spine and U. S.

Orthopedics, improve margins and generate free cash flow. These investments are expected to position the company for both near and long term profitable growth. With that context, let me walk you through our financial results for the quarter. In the second quarter, total global net sales reached $200,700,000 up 4% over the prior year. I will now take you through the net sales results by product segment.

Global Spinal Implants, Biologics and Enabling Technologies second quarter pro form a net sales were $104,800,000 with year over year growth of 2%. These results were in line with our expectations due to the anticipated short term impact from targeted distributor transitions in key geographies impacting both our U. S. Spine and Biologics businesses. In our U.

S. Spine Fixation business, procedure volume increased by 7%. However, this growth was partially offset by an outsized impact from a price decrease at a major account that we mentioned during our first quarter call. We will be working through this for the remainder of the year. We continue to see strong adoption of our 7D flash navigation system with total U.

S. Unit placements in the 2025 growing by 66% over the same period of the prior year. Moving to Bone Growth Therapies, BTT continues to achieve strong net sales growth exceeding market performance in the second quarter. Total net sales reached $62,600,000 reflecting 6% growth. This expansion was supported by strong results in both the spine and fracture channels.

Fracture growth within BGT was 7% attributed to investments in the fracture sales channel that have led to new surgeon conversions. We do expect our BGT growth to remain at or above market growth rates currently estimated to be 2% to 3%. We will continue to focus on adding new surgeons and competitive surgeon conversions in BGT Spine and continue our commercial focus in the BGT fracture market where we currently have lower market penetration and see a substantial opportunity to drive new business with orthopedic surgeons. The global orthopedics business grew 5% to $33,300,000 in the second quarter led by 28 growth in The U. S.

As a result of the limited market release of TRULOC Elevate and the full market launch of the FITBONE Bone Transport Nail. The international orthopedics business declined 2% in line with our expectations due to several large NGO orders that occurred in 2024 that did not repeat in 2025. As we previously commented, due to the nature of this business, particularly around the timing and volume of stocking distributor and tender orders, we expect to see variability in the growth rates from quarter to quarter. Moving down the P and L, pro form a non GAAP adjusted gross margin, which excludes the impact of the M6 discontinuation, reached 72.7%, representing an approximate 140 basis point increase compared to the reported non GAAP adjusted gross margin for the 2024 of 71.3%. This improvement was primarily driven by the discontinuation of M6 and favorable product mix.

Pro form a non GAAP adjusted EBITDA excluding the impact of the discontinuation of M6 was $20,600,000 or 10.3% of net sales. Pro form a adjusted EBITDA margin expanded approximately 190 basis points compared to reported non GAAP adjusted EBITDA margin for the 2024 of 8.4%. The discontinuation of M6, which has been a negative drag on our profitability in prior periods, drove about one half of this improvement with the remaining gains resulting from favorable product mix and the actions to optimize our shared service functions announced in Q1 accounting for the remaining half. We are pleased by these margin expansion results as we see our ability to drive leverage on sales growth materializing as we continue to focus on disciplined profitable growth. From a cash standpoint, our total cash balance at the end of Q2 including restricted cash increased to $68,700,000 driven by positive free cash flow of $4,500,000 for the second quarter.

Overall, we continue to be confident in our ability to drive profitable revenue growth moving forward. We remain focused on pursuing the vital few initiatives in our long range plan and prudently deploying capital and resources to areas where we have a differentiated advantage, all of which we believe will support the achievement of our three year financial targets and propel our business forward. Moving on to 2025 full year guidance. First, regarding tariffs, we have exposure to tariffs in The EU, Canada, China and Taiwan. We estimate our annual exposure to be in the range of 3,000,000 to $4,000,000 consistent with our comments in Q1.

This estimate includes currently applicable U. S. Tariffs that took effect on August 1 and assumes such tariffs remain in place. This exposure is very manageable, primarily reflected in cost of goods sold and already contemplated in our guidance. We maintain our expectation of full year pro form a net sales between $8.00 $8,000,000 and $816,000,000 excluding revenue from the discontinued M6 product lines.

We expect third quarter twenty twenty five net sales to be similar to the second quarter with new distributor partners helping to counter usual seasonal declines in procedure volumes. These projections are based on current foreign currency exchange rates and do not assume any additional changes to exchange rates during the remainder of the year. We continue to expect full year 2025 pro form a non GAAP adjusted EBITDA of $82,000,000 to $86,000,000 This range includes the anticipated impact from the discontinuation of the N6 product lines that was previously announced in February 2025 and represents 190 basis points of EBITDA margin expansion at the midpoint of the range compared to 2024. We also continue to expect to generate positive free cash flow for the full year 2025 excluding the impact of restructuring charges related to the discontinuation of M6 product lines. Additionally, we expect to generate positive free cash flow for the 2025.

Now for some specifics on individual line items for the P and L for 2025. We expect our gross margins to be approximately 72% for the remainder of the year. We continue to expect our operating expenses to improve by approximately 200 basis points this year versus 2024. We now expect stock based compensation of approximately $28,000,000 to $29,000,000 and adjusted depreciation and amortization of approximately $37,000,000 for the full year and interest and other expenses of approximately $5,000,000 per quarter. Finally, building on a resilient financial foundation and delivering long term shareholder value will continue to be paramount in 2025 and beyond, driven by our heightened focus on disciplined profitable growth, positive cash flow generation and strategic capital deployment.

Now before we open up the call for questions, let me turn it back to Massimo for concluding comments. Massimo?

Massimo Colifiori, President and Chief Executive Officer, Orthofix: Thanks, Julie. I want to thank our Orthofix team and our committed commercial partners for their effort in Q2. In the back half of the year, we had a significant opportunity to drive profitable growth and leverage positive momentum. We executed two of the most exciting product introductions in Orthofix history with Verada in its early stage evaluation period and TRULOC Elevate now fully launched. We remain committed to our focused commercial strategy, a surgeon centric innovation pipeline and a clear trajectory toward expanded margin.

I believe we are poised to achieve our financial goals and generate sustainable long term value for our shareholders. Operator, let’s now open the line for questions.

Kayla, Conference Operator: Your first question comes from the line of Mike Petusky with Barrington Research. Your line is open.

Mike Petusky, Analyst, Barrington Research: Hey, good morning. I guess I wanted to start just asking about the U. S. Orthopedics results. I mean, that being driven by just deeper utilization of the products sort of among the existing customer base?

Or are you guys adding new accounts, new surgeons in U. S. Orthopedics? Just curious what’s the driver there primarily?

Massimo Colifiori, President and Chief Executive Officer, Orthofix: Yes. Hi, good morning, Mike. I think that the driver is both. We can keep the deeper in the account where that we already doing business given our stronger and wider product portfolio. But most importantly, I think that the introduction of TRULOC Elevate or TBT is helping us to enter on a market, but we were not participating.

TRULOC Transverse is unique product that help us to participate this $1,700,000,000 diabetes food market. And the result that we are seeing is very remarkable, avoiding amputation to all of the patient that we treated so far. So we had over two hundred cases just done and a very high demand out there. So we are very pleased about the what we are gaining from our new focus strategy on complex limb reconstruction that is creating a unique position for us in the marketplace. Because also you need to remember that on top of the TBT with our FeetBone product line, we are the only company in the world right now the only company in The United States, sorry, that can provide internal and external solution for also for bond transport.

So again, I’m very pleased of this new product launches. I’m very pleased of the strategy and the results are speaking by itself.

Mike Petusky, Analyst, Barrington Research: Terrific. If I could just sneak a quick one in there for Julie as well. Julie, on the free cash flow, obviously, good number. I’m just curious, CapEx was a little bit lighter than we had anticipated. Is there and I may have missed this, but is there a guide for CapEx for the back half?

And then is there any reason you shouldn’t see sequential improvements in free cash for the remainder of the year? Thanks.

Julie Andrews, Chief Financial Officer, Orthofix: Hi, Mike. So I’ll start with kind of your last part of your question first. You know, our comments are specific that h two will be free cash flow positive, but not not necessarily each quarter. And generally speaking, you know, q four will be cash flow positive, and we may see a little slow slow down in q three. We don’t have a specific guide for CapEx, but it’s probably gonna you know, was a little bit lighter this quarter.

Probably, it’s a little bit heavier in q three. But overall, you know, approximately, you know, flat to last year.

Massimo Colifiori, President and Chief Executive Officer, Orthofix: Thank you.

Kayla, Conference Operator: And your next question comes from the line of Caitlin Cronin with Canaccord. Your line is open.

Caitlin Cronin, Analyst, Canaccord: Hi. Congrats on a good quarter. Thanks for taking the questions. You know, just to to talk about The US fine distributor transition, some more color on how that’s going. I mean, any changes to the strategy or the timing versus last quarter, particularly given the q three guidance commentary and, you know, when you expect to see accelerated growth?

Massimo Colifiori, President and Chief Executive Officer, Orthofix: You know, like, as we said, first of all, we believe we are very pleased about the interest that we have that that we are seeing on our on our company. So and I’m very pleased about how the commercial is executing all of the transition that we start to talk about in Q1. You saw already some acceleration on this quarter, but I’m very let’s say, I’m very excited about the effect that it’s going to have on our company in the from Q3 and beyond. I think that this going to all of this work that we’re doing is gonna help us to bring the company back to the a more a bull market CAGR that we that we discussed in our three year financial plan. So where we are today and why I feel very confident about the business is because all of these initiatives are creating a much stronger foundation.

So besides, you know, besides our commercial our you know, besides the commercial the commercial side of the equation, as as you see, our innovation pipeline is very strong. Verada is going to be a great contributor for our the growth of our company from now on for the next few years. The demand for 70 is very is very high. I think that having this highly differentiable product, enabling technology platform is helping the team to keep recruiting the talent that we want. So all in all, between our commercial execution and our focus on innovation, I feel very confident about, what is gonna what we can achieve from now on.

Caitlin Cronin, Analyst, Canaccord: That’s great. And then strong BGT growth, Xcelsim two point zero, have you launched that yet? And any contribution expected from that launch in the second half?

Massimo Colifiori, President and Chief Executive Officer, Orthofix: Yes. We’re gonna it is was FDA approved, and we are planning to launch it in the second half of the year. We’re gonna see some contribution of the product, but most importantly, the fact that it’s going to connect in a seamless way with our post op platform, we see a lot of interest on the surgeon given the ability to follow patient when during the healing journey. So I cannot be more proud about what the BGT team is doing. If you think about being the market leader and posting quarter over quarter this substantial growth is just a testament about our commercial excellence,

Mike Petusky, Analyst, Barrington Research: but

Massimo Colifiori, President and Chief Executive Officer, Orthofix: also our ability to leverage the cross selling opportunities that are appearing both in spine and in orthopedics. Because the fact that our orthopedics business is growing so fast in United States is going just accelerate also our opportunity to cross sell into BGT. So I can firmly say that our strategy also in the BGT is working.

Caitlin Cronin, Analyst, Canaccord: Great. Thanks for taking the questions.

Kayla, Conference Operator: And your next question comes from the line of Jeffrey Cohen with Ladenburg. Your line is open.

Jeffrey Cohen, Analyst, Ladenburg: Good morning, Massimo and Julius. Thanks for taking our questions. I wondered if firstly you could talk about seven d and geographically speaking some of the traction that you’re seeing now and what you anticipate in the back half from a geographical standpoint.

Massimo Colifiori, President and Chief Executive Officer, Orthofix: We are not talking about the seven d from the geographic point of view. I think that we are the results of of seven d right now are very compelling, are demonstrating the quality of our strategy. The 70 unit placement grew 66% in the 2025. But most importantly, it’s giving us a revenue commitment of around $12,000,000 over the lifetime of the contract. Think about normally this commitment at three, four years, but what really what is really great for us is that over that the majority of our placement are on average 50% on top of what the commitment purchase commitment for hardware biologics.

So again, we are not talking about where we place 7D geographically, but thinking about United States, very pleased with the success of our Voyager and Out program.

Jeffrey Cohen, Analyst, Ladenburg: Thank you. That’s helpful. And then secondly for us, could you talk about was there any pricing that you were able to take during the second quarter? Is there any pricing, anticipated, for the back half of the year?

Julie Andrews, Chief Financial Officer, Orthofix: Yeah. I mean, there weren’t any pricing changes in the quarter, compared to, you know, our comments in q one. We did talk in q one about we had, you know, a pricing contract that went into effect and an account that is having a, you know, a a sizable impact on our spine fixation business. But that’s that’s not new. That’ll continue for the rest of the year.

But other than that, pricing was pretty stable.

Jeffrey Cohen, Analyst, Ladenburg: Got it. Okay. Perfect. Thanks for taking our questions.

Kayla, Conference Operator: Your next question comes from the line of Jason Wittes with Roth. Your line is open.

Jason Wittes, Analyst, Roth: Hi, thanks for taking the questions. Just looking at the growth over the last few quarters and even the outlook, it seems like you have a very big opportunity in specialized ortho. If you look forward, is that kind of where you think you’re going to continue to see outsized growth for the business?

Massimo Colifiori, President and Chief Executive Officer, Orthofix: Yes. I think that look, we are working very hard, of course, to balance the growth within all our business units. But it’s clear that the strategy that we implemented around orthopedics especially in United States is paying off. We are redefining the category of limb reconstruction is under several market that comprehensive or limb preservation deformity correction, limb lengthening and complex structure management. And the combination of TBT and FeetBone and our legacy product is creating a unique position that we gonna try that we are working very hard to fully capitalize.

And I don’t see the business and the growth in United States slowing down in the foreseeable future. So very excited to participate on this $1,700,000,000 market with our product line. But again, the success of the organization is gonna come from the combination of our growth in spine. The investment that we’re making on our distribution is paving and is creating a stronger foundation for us. The growth that we’re experiencing in BGT quarter over quarter is amazing.

So very confident about the ability to this organization to deliver in the foreseeable future.

Jason Wittes, Analyst, Roth: Okay. That’s helpful. And then also looking at Bone Growth Therapies, that’s also continuing to grow above market at least kind of where even you guys see where the market is growing. How much is that product driven and how much of that is cross selling, which I think initially was a big part of the growth we saw when you first merged with C Spine?

Massimo Colifiori, President and Chief Executive Officer, Orthofix: Yes. Well, we will continue to focus on cross selling with Orthopedics and Spine. The growth in Orthopedics is also helping to capitalize to this opportunity even farther. We are driving are helping to we are planning to drive penetration in the BGT fracture in the second half with Axos team. But, again, I think that the majority of our success is coming from our ability to execute commercially quarter over quarter, giving also the highly differentiable back office that we have that creates a very unique and easy to know and a very unique seamless opportunity for our patient and surgeon that prescribe and use BGT.

Jason Wittes, Analyst, Roth: Okay, great. Maybe just one last one. The large customer that impacted pricing in in the first quarter. I don’t if that’s something you can quantitate going forward, and I assume that will anniversary, I guess, first quarter next year. Just your thoughts on that.

Julie Andrews, Chief Financial Officer, Orthofix: Yeah. So, Jason, we said our volume growth was 7% and overall growth was was 5.4%. So that’s basically the differences of pricing.

Jason Wittes, Analyst, Roth: So but it’s all due to that single customer or that’s that’s, I assume, pricing across the board?

Julie Andrews, Chief Financial Officer, Orthofix: The the vast majority of it is due to that that customer.

Jason Wittes, Analyst, Roth: And

Kayla, Conference Operator: there are no further questions at this time. Julie Dooley, I turn the call back over to you.

Julie Dewey, Chief IR and Communications Officer, Orthofix: Great. Thank you, Kayla, and thanks everybody for joining us today. Your time and interest in Orthofix is appreciated. If you have questions, please reach out. We look forward to talking to

Julie Andrews, Chief Financial Officer, Orthofix: you next quarter. This concludes our call.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.